Information Provided By: 
Fly News Breaks for April 9, 2019
ZGNX
Apr 9, 2019 | 09:26 EDT
Empire Asset Management views the selloff in shares of Zogenix after the company received a Refusal to File Letter for Fintepla as a buying opportunity. The FDA did not seem to indicate that additional clinical efficacy or safety data was needed, Empire tells investors in a research note. Further, the firm points out that Fintepla has FDA Breakthrough Therapy Designation and Fast-Track status, which it believes should expedite Zogenix's timeline to an FDA Type A meeting. Empire keeps a Buy rating on the shares with a $66 price target.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
